drugset / Trial / NCT00148837
Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Phase 2
Completed
112 enrolled
French National Agency for Research on AIDS and Viral Hepatitis
Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.
Timeline
- Start
- 2004-09
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prazosin | Unknown | 5 mg | — |
| Background | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | — |
| Background | Ribavirin | Small molecule | 1000 mg | — |
| Background | Ribavirin | Small molecule | 1200 mg | — |